Brett T. Brinker, Susan E. Krown, Jeannette Y. Lee, Ethel Cesarman, Amy Chadburn, Lawrence D. Kaplan, David H. Henry and Jamie H. Von Roenn Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma Cancer 112
Version of Record online: 25 JAN 2008 | DOI: 10.1002/cncr.23108
The safety and efficacy of a novel, orally bioavailable matrix metalloproteinase inhibitor, BMS-275291, was evaluated in patients with human immunodeficiency virus-associated Kaposi sarcoma and the relation between changes in the percentage of apoptotic cells in tumor biopsies and response was investigated. Unacceptable toxicity and inadequate efficacy precluded further development of this agent, and an attempt to use apoptosis as a surrogate for response was unsuccessful.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field